Stock 4523 EISAI CO., LTD.
Add to a list

ETFs Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 12:00:00 12/06/2026 pm IST 		5-day change 1st Jan Change
3,780.00 JPY +1.53% Intraday chart for Eisai Co., Ltd. +0.13% -18.88%
11/06 Beren Therapeutics P.B.C. announced that it has received $245 million in funding from Eisai Co., Ltd., The Founders Fund, LLC, Wellington Partners Advisory AG, Narya Capital, JIC Venture Growth Investments Co., Ltd. and other investors CI
04/06 Eisai Co., Ltd. Announces Issuance of Unsecured Straight Bonds CI

ETFs positioned on Eisai Co., Ltd.

Name YTD change Weight AuM
NOMURA NIKKEI 225 EXCHANGE TRADED FUND ETF - JPY ETF Nomura Nikkei 225 Exchange Traded Fund ETF - JPY
+32.05%0.71% 85,612 M€
NOMURA NEXT FUNDS MSCI JAPAN EMPOWERING WOMEN SELECT INDEX ETF - JPY ETF Nomura NEXT FUNDS MSCI Japan Empowering Women Select Index ETF - JPY
+20.20%0.32% 77 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
+7.24%0.06% 33,076 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF - Distributing - EUR
+4.48%0.02% 37 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF - Distributing - EUR
+1.99%0.01% 15 M€
12

Company Profile

Logo Eisai Co., Ltd.
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Employees
10,917
Sector
Pharmaceuticals
Calendar
Earnings release - Q1 2027
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3,780.00JPY
Average target price
4,607.69JPY
Spread / Average Target
+21.90%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. 4523 Stock
  4. ETFs Eisai Co., Ltd.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition